In the career of an HBP surgeon, a single, deeply memorable case can sometimes offer more profound lessons than large-scale studies. This session invites submissions on "unforgettable case experiences" that go beyond mere reports of rarity to offer insights that can transform our clinical practice.
We invite you to share the "take-home messages" derived from these experiences, whether it was an ingenious solution that overcame a life-threatening intraoperative crisis, a case that pushed the boundaries of standard care, or a humbling experience that overturned your own assumptions. We look forward to a vibrant discussion aimed at passing down the surgeon's thought processes, decision-making rationale, and the new insights gained from difficult situations as a valuable legacy for the next generation.
This session is designed for beginners aspiring to engage in clinical research, covering three essential elements: medical statistics, specified clinical trials, and dry analysis. A fundamental understanding of medical statistics is indispensable for designing research protocols and interpreting results and is critical to the quality of research. In the field of specified clinical trials, a thorough understanding of the regulatory and ethical frameworks, as well as their proper application, is crucial. Dry analysis is gaining attention as an efficient approach to derive clinically meaningful insights. In this session, experts will use real-world examples to provide participants with the essential knowledge to embark on research. We hope this will serve as a valuable opportunity for young clinicians with limited research experience to take their first steps into both basic and clinical research.
HBP surgery is a field that demands advanced techniques, extensive knowledge, and a long-term commitment to training. In recent years, attracting and training the next generation of talent has become a critical challenge, driven in part by a declining interest in surgical careers and a shifting work environment shaped by new regulations on physician work hours.
To address this, recruiting young doctors requires effectively communicating the appeal and rewards of the specialty, presenting flexible and compelling career paths, and creating a supportive and sustainable work environment. On the educational front, it is essential to provide phased, systematic surgical training and opportunities for research.
This session will serve as a forum to share best practices, innovative initiatives, and current challenges from various institutions and regions. We aim to explore, from multiple perspectives, how to best recruit, train, and retain the next generation of HBP surgeons.
Improving 5-year survival rates is a common goal for all clinicians treating pancreatic cancer. Recent advances in treatment strategies have enabled previously unimaginable improvements in long-term prognosis. This symposium aims to share institutional treatment strategies and clarify pathways to achieving "5-year pancreatic cancer survival."
We invite presentations on practical treatment strategies based on real-world clinical experience, including optimal sequencing of multi-agent chemotherapy, effective initiation of radiation therapy, and optimal indications and timing for conversion surgery. From evidence-based standard approaches to institution-specific innovations, we aim to advance this field through presentations of diverse treatment strategies and detailed long-term survival case analyses.
Recent advances in systemic therapy for hepatocellular carcinoma (HCC) have been remarkable, and the oncological resectability classification proposed in Japan has brought increasing attention to treatment strategies for Borderline Resectable (BR) HCC. While multidisciplinary treatments have increased resection opportunities, the optimal strategy is still evolving, and the prognostic factors that truly identify patients who can achieve long-term survival remain unclear.
This symposium aims to discuss the factors that contribute to long-term survival in BR HCC from a broad perspective. We invite presentations on institutional treatment strategies, optimal patient selection, timing and technical aspects of surgery, long-term outcomes, and prognostic factors.
Although biliary tract cancer remains a disease with a poor prognosis, the recent introduction of immune checkpoint inhibitors and advances in genomic medicine are bringing about a paradigm shift in medical therapy. The advent of these powerful systemic treatments is expanding the potential for surgical intervention for advanced biliary tract cancer previously considered unresectable. However, an optimal multidisciplinary treatment strategy to translate these new options into long-term survival has not yet been established.
This symposium aims to discuss the role of surgery within this new treatment paradigm and to explore new strategies for achieving long-term survival. We particularly invite submissions on topics that could form the cornerstone of the future standard of care, such as the indications and timing for conversion surgery, the optimization of neoadjuvant and adjuvant therapy, and the integration of surgery with personalized treatments based on genomic information.
Treatment options for UR-M pancreatic cancer have diversified, yet clinicians often struggle with selecting appropriate strategies and timing for each metastatic pattern. This session will facilitate in-depth discussions on the rationale of decision-making and optimal timing for treatment transitions, based on institutional experience with CY-positive, hepatic, and pulmonary metastatic cases.
We invite presentations on practical challenges encountered in real-world clinical settings, such as: re-evaluation methods and conversion timing in CY-positive cases, conversion surgery criteria for hepatic metastases, treatment selection rationale for pulmonary metastases (radiation, RFA, surgery), and timing for treatment transitions. We seek presentations addressing these challenges to help establish optimal treatment strategies, including institutional treatment practices, decision criteria, and case-based insights.
Preoperative evaluation of anatomically resectable pancreatic cancer with high biological malignancy remains challenging. While evaluation has centered on imaging and CA19-9, emerging biomarkers and research advances may enable new assessment approaches.
This panel will examine the utility of conventional clinical evaluations including imaging and tumor markers, and explore the clinical applicability of new biomarkers like liquid biopsy (ctDNA, exosomes, CTC), novel molecular markers, and imaging AI for guiding resection decisions.
We invite presentations from both surgical and basic research perspectives. This session will discuss the potential and limitations of conventional methods, share the latest findings from novel biomarker research, and ultimately aim to establish optimal evaluation methods for Biological Borderline Resectable pancreatic cancer.
Hepatic resection is the most established curative treatment for colorectal liver metastases (CRLM), offering the potential for long-term survival. While multidisciplinary treatment has become the standard approach, the postoperative recurrence rate remains high, and only a limited number of patients achieve true long-term survival. The introduction of potent chemotherapy regimens has recently posed new challenges in determining resection indications and surgical timing.
This session will focus on the core treatment strategies for achieving long-term prognosis after resection of CRLM. We welcome presentations from diverse perspectives on how each institution combines chemotherapy and surgery to improve prognosis, including the rationale behind their strategies and the resulting treatment outcomes.
Liver transplantation has become an established treatment for end-stage liver disease, with survival exceeding 20 years now a reality. This represents a significant "achievement" in the field of liver transplantation in Japan. However, beyond long-term survival, new "challenges" are emerging, such as controlling the recurrence of the primary disease, managing complications like renal dysfunction and cardiovascular events due to immunosuppressive therapy, and addressing the aging of both donors and recipients.
This panel discussion aims to explore concrete measures to overcome these challenges and truly improve post-transplant outcomes, including both prognosis and QOL. We invite presentations on each institution's long-term management approaches, clinical results, and current issues. Based on these discussions, this session will serve as a forum to collectively discuss and envision future standard management guidelines and the direction of transplant medicine.
Perihilar cholangiocarcinoma is one of the most challenging malignancies in HBP surgery, and its treatment strategy remains a subject of considerable debate. Improving outcomes hinges on optimizing surgical procedures based on precise preoperative staging; performing safe extended hepatectomy utilizing tools such as portal vein embolization and appropriate biliary drainage, and introducing multidisciplinary approaches like adjuvant therapy or liver transplantation to push beyond the limits of extended surgery.
This panel discussion aims to improve outcomes for this intractable cancer. We invite presentations on each institution's approaches, outcomes, and ongoing challenges—from preoperative evaluation to surgical decision-making, perioperative management, and the implementation of multidisciplinary care—creating a forum to envision the future standard of care for this disease.
This session invites presentations on best practices that concretely demonstrate how collaboration with other departments, such as Gastroenterology and Interventional Radiology (IVR), has contributed to improving perioperative safety and treatment outcomes.
We encourage submissions on systematic collaborative approaches to specific clinical challenges and their quantitative evaluation, such as optimizing preoperative biliary drainage strategies, determining the indications and timing for portal vein embolization, managing post-pancreatectomy hemorrhage with IVR, or developing multidisciplinary protocols for conversion surgery. This session will serve as a forum not only to introduce collaborative frameworks but also to share concrete clinical insights gained through practice and to discuss new strategies for perioperative management.
Total pancreatectomy remains an important treatment option for extensive IPMN and remnant pancreatic cancer. As long-term survivors increase, addressing complications specific to total pancreatectomy has become increasingly important.
Post-total pancreatectomy patients require unique blood glucose management and face long-term complications including digestive absorption disorders and fatty liver progression to cirrhosis.
This workshop aims to establish better long-term management methods through presentations of institutional experience and follow-up data, addressing glucose management, enzyme replacement optimization, nutritional strategies, and fatty liver prevention in post-total pancreatectomy patients.
With advances in multidisciplinary treatment, parenchyma-sparing surgery for pancreatic cancer has gained attention. These procedures balance tumor control with pancreatic function preservation for improved postoperative QOL, but require further assessment of their long-term oncological safety.
This workshop examines long-term outcomes of parenchyma-sparing surgery for pancreatic cancer. We seek presentations of institutional follow-up data addressing preoperative treatment necessity, stage-based indications, optimal lymph node dissection extent, adjuvant therapy needs, and their impact on long-term prognosis and recurrence patterns. We aim to evaluate the true oncological validity and establish appropriate indication criteria for parenchyma-sparing surgery.
Conversion surgery for locally advanced pancreatic cancer is an important treatment strategy, yet some patients do not achieve sufficient benefit despite surgical resection. This workshop objectively examines the benefits and risks of conversion surgery from multiple perspectives.
We seek presentations analyzing patient backgrounds and treatment courses in cases with favorable long-term outcomes, and examining objective indicators for surgical decisions. In parallel, we invite presentations identifying which patients derive limited benefit from surgical intervention, based on an analysis of cases with poor prognosis and early recurrence.
We aim to foster a multi-institutional discussion on conditions for conversion surgery that truly improve patient prognosis, including preoperative regimens, optimal surgical timing, and adjuvant therapy selection.
In pancreatic neuroendocrine tumor (NET) treatment, peptide receptor radionuclide therapy (PRRT) has become available as a new treatment option in addition to conventional surgery and medical therapy. This expansion of treatment options requires reconsideration of pancreatic NET treatment strategies.
This workshop will facilitate discussions on current pancreatic NET treatment strategies with expanded therapeutic options. We will examine the selection criteria and sequencing for surgery, medical therapy, and PRRT, indications for each treatment modality, and development of treatment algorithms incorporating PRRT. We aim to share institutional case experiences and changes in treatment strategies to standardize and improve pancreatic NET care.
Important challenges remain in IPMN management even after international guideline revisions. Treatment strategies for post-resection recurrence/metastasis and progressive cases during surveillance lack established standard guidelines and represent difficult clinical challenges.
This workshop will share institutional treatment experiences with these patient groups and examine practical management approaches. We expect valuable discussions on treatment strategies in these evidence-limited areas, including treatment selection rationale for recurrent/metastatic cases, indications and efficacy of chemotherapy for unresectable progressive cases, and decision-making criteria for treatment planning.
Advances in systemic therapy, including immune checkpoint inhibitors, have significantly changed the treatment landscape for unresectable hepatocellular carcinoma, creating a new strategy known as conversion surgery. While this has opened a path to cure for some patients, assessing its true value requires the accumulation and analysis of treatment outcomes. The purpose of this session is to evaluate the treatment outcomes of this new approach from multiple perspectives.
Which patients are good candidates for conversion surgery? What are the effective drug regimens, and what is the optimal duration of treatment before surgery? Most importantly, what factors determine long-term prognosis after resection? We invite presentations on treatment outcomes from each institution—including R0 resection rates, postoperative complications, and survival rates—and look forward to a robust discussion aimed at standardizing this treatment strategy.
Hepatocellular carcinoma (HCC) is characterized by a high recurrence rate, and appropriate treatment strategies for recurrence are crucial for long-term prognosis. The choice of treatment for recurrence requires a comprehensive evaluation of multiple factors, including tumor characteristics, remnant liver function, and overall patient condition, to select the best option from repeat hepatectomy, local therapies, liver transplantation, or systemic therapy.
Recently, advances in molecular targeted agents and immune checkpoint inhibitors have broadened systemic treatment options, increasing the importance of combining these therapies with surgical or locoregional therapies.
This session welcomes a broad discussion on the latest treatment strategies for recurrent HCC, the evidence supporting them, and the challenges and innovations in real-world clinical practice.
In liver resection, pursuing oncologic radicality while preserving postoperative liver function is a constant trade-off faced by surgeons. Striking the optimal balance is directly linked to improving true long-term prognosis. Recent advances in preoperative simulation technology and the emergence of various techniques have led to a wider range of available strategies. Each institution is developing various approaches, from exploring the limits of extended hepatectomy to performing precise resections that spare the liver parenchyma.
This session aims to discuss surgical strategies for finding the optimal balance between radicality and functional preservation. We invite presentations on topics such as determining the extent of resection based on precise liver function assessment, technical innovations for maximizing parenchyma preservation, and treatment outcomes that validate these approaches.
Intrahepatic cholangiocarcinoma (ICC) remains a malignancy with a poor prognosis, and improving its treatment outcomes is a significant challenge in the HBP field. While surgical resection offers the only chance for a cure, the extremely high recurrence rate makes the long-term outlook dismal. To overcome this situation, both improving the quality of surgery itself and strategically integrating it with new treatment modalities are essential. The reconstruction of multidisciplinary treatment, combining surgical innovations like optimizing the extent of hepatectomy and lymph node dissection with medical therapies, represents our current "challenge."
This session will discuss new treatment strategies centered on surgery to improve the prognosis of this intractable cancer. We invite presentations on ambitious approaches and their treatment outcomes, including the pursuit of optimal extent of hepatectomy and lymphadenectomy, novel attempts at neoadjuvant and adjuvant therapy, and the integration of surgery with personalized medicine based on genomic data, to collectively envision the future of ICC treatment.
Many clinical questions in the management of gallbladder cancer remain unresolved. There is no clear consensus on issues such as the indications for additional resection for pT1b tumors, the optimal extent of hepatectomy and lymph node dissection for advanced cancer, and the role of perioperative adjuvant therapy, leading to significant variability in practice among institutions.
To address these important issues and achieve true prognostic improvement, an objective evaluation based on long-term outcomes is essential. This session aims to be a forum for discussing stage-specific optimal treatment strategies for gallbladder cancer based on long-term results.
While surgical resection is the only curative treatment for non-ampullary duodenal cancer, procedures range from pancreaticoduodenectomy (PD) to various parenchyma-sparing surgeries. The core challenge in treating this disease is how to best balance oncological radicality with the preservation of postoperative function. However, a consensus has yet to be established regarding procedure selection and the optimal extent of lymph node dissection to strike this balance. To address this important issue and establish a true standard of care, it is essential to compare and validate the long-term outcomes of each procedure based on objective data.
This workshop aims to shed light on this challenge from the dual perspectives of long-term outcomes and QOL. We invite high-quality submissions that explore the optimal balance between radicality and functional preservation, including comparisons of long-term survival between different procedures, objective data on postoperative nutritional status and QOL, and institution-specific surgical algorithms based on such data. We hope to create a forum for discussion aimed at establishing a true standard of care.
Artificial intelligence (AI) technologies are being rapidly integrated into all aspects of medicine, and their applications in hepatobiliary and pancreatic surgery are expanding to include preoperative diagnostic support, prognosis prediction, surgical navigation, and image analysis. Moreover, AI is providing new perspectives in basic research fields such as the analysis of large-scale omics data and drug discovery support. This session will comprehensively address the current landscape, challenges, and future prospects of AI utilization in hepatobiliary and pancreatic surgery, with a particular focus on bridging cutting-edge innovations to real-world clinical practice.
High-quality HBP surgical care is robustly practiced in community hospitals throughout Japan, playing a vital role as a cornerstone of regional healthcare. This session invites presentations on ingenious approaches that leverage the unique characteristics of the community hospital setting and on practical experiences that warrant wider dissemination.
We welcome reports rooted in real-world clinical practice, such as the establishment of HBP surgical teams and educational systems, the development and implementation of resource-conscious perioperative management protocols, the analysis of quality improvement and cost-reduction effects from introducing clinical pathways, or the specific strategies for intra- and inter-institutional collaboration on difficult cases. We look forward to a thought-provoking discussion that, from a perspective different from that of university hospitals and cancer centers, will contribute to raising the standard of HBP surgical care in Japan.
Hepatobiliary and pancreatic cancers remain highly aggressive malignancies with poor prognoses, and breakthrough advances in diagnosis and treatment are eagerly awaited. In recent years, surgeons have led translational research integrating genetic and molecular profiling of patient-derived specimens with insights from comprehensive clinical data. The introduction of new technologies—including genomic analysis, multi-omics profiling, liquid biopsy, and AI-based analytics—is broadening our understanding of tumor biology and opening new avenues for personalized medicine. In this session, we invite presentations on the latest research bridging basic science and clinical practice in hepatobiliary and pancreatic cancers, and look forward to active discussions on their significance and future perspectives.
Achieving board certification as an expert HBP surgeon requires the knowledge and skills to safely perform highly complex procedures. With the increasing adoption of minimally invasive surgery in recent years, a key challenge has emerged: how to effectively translate limited case opportunities into meaningful educational experiences.
This workshop will focus on sharing concrete educational programs and innovative approaches from various institutions aimed at training future expert surgeons. Topics will include strategies for securing training opportunities and methods for providing effective feedback. Our goal is to explore practical measures that can be applied to surgical training starting tomorrow.
As robot-assisted pancreaticoduodenectomy continues to be adopted, establishing safe and efficient techniques has become an important challenge due to technical characteristics that differ from conventional open and laparoscopic surgery. Standardized techniques are needed to shorten the learning curve and ensure consistent surgical outcomes.
This video symposium will present standardized surgical techniques being developed at each institution. We invite presentations with video demonstrations of practical techniques that contribute to reduced operative time and improved safety, including standardized resection procedures and efficient lymph node dissection techniques, to serve as a forum for sharing valuable insights toward technical standardization.
Minimally invasive hepatectomy has established its position as a standard procedure, with its indications now expanding to include complex hepatectomies. However, performing these surgeries safely and reliably requires advanced techniques and innovations distinct from open surgery.
The purpose of this video symposium is to share specific surgical techniques and the "Tips & Tricks" for successfully performing complex minimally invasive hepatectomies. We invite video presentations demonstrating surgical techniques for complex procedures such as resection of the posterosuperior segments or extended hepatectomy via laparoscopic or robotic-assisted approaches; safe dissection around the hepatic hilum or the major hepatic veins; and the practical application of advanced technologies like ICG fluorescence and 3D navigation. Through the demonstration and discussion of these techniques, we aim to advance the standardization and safety of procedures in this field.
Minimally invasive surgery for biliary tract cancer represents one of the most formidable challenges in the field of HBP surgery. To ensure oncologic radicality, it requires lymph node dissection and safe, reliable biliary and vascular reconstruction comparable to open surgery, demanding extremely high level of technical skill.
This video symposium will focus on the specific surgical techniques and the decision-making criteria that enable the success of these complex procedures. We invite presentations of surgical techniques from various institutions, such as lymph node dissection for gallbladder cancer, pancreaticoduodenectomy for distal bile duct cancer, and procedures requiring complex biliary reconstruction. Submissions highlighting innovations in robotic-assisted surgery are particularly welcome. We hope that sharing techniques and discussing them through video presentations will contribute to improving the safety and promoting the responsible adoption of this challenging surgery.
Reconstruction techniques in robot-assisted pancreaticoduodenectomy are crucial technical elements that determine surgical success. This video workshop will share various reconstruction techniques and innovations from each institution, to establish reconstruction methods that maximize the advantages of precise manipulation through multi-jointed instruments and build systems for technical skill transfer.
We expect presentations with video demonstrations of practical techniques including optimized pancreaticojejunostomy and choledochojejunostomy procedures, and innovations for complication prevention. Through detailed technical explanations using surgical videos, we aim to create a forum that contributes to technical improvement and the safe surgical dissemination.
With the spread of laparoscopic and robotic-assisted surgery, the ability to appropriately manage intraoperative troubles that arise in this unique environment has become an essential skill for all HBP surgeons. This session invites presentations on concrete and practical techniques focused on the prevention and management of intraoperative complications in minimally invasive surgery.
We ask presenters to share their core troubleshooting strategies based on their own institutional experience, such as controlling bleeding from the hepatic vein or portal vein, overcoming difficulties in dissection for cases with severe adhesions or inflammation, and establishing clear decision-making criteria for a safe conversion to open surgery. Video-based presentations demonstrating specific techniques are highly encouraged, creating a forum to share knowledge aimed at further enhancing the safety of minimally invasive HBP surgery.
In modern practice, open surgery is often selected for the most complex and difficult cases, or as a bailout from minimally invasive procedures. Consequently, intraoperative troubles in these situations can present formidable challenges. This session invites presentations on advanced surgical strategies for overcoming such critical situations.
We welcome presentations on judgment and techniques in extreme situations that test a surgeon's comprehensive skills, such as the repair and reconstruction of major vascular injuries under total vascular exclusion, salvage procedures when standard techniques fail, or emergency extension of the resection margin based on intraoperative frozen section diagnosis. Reports on "bailout" techniques for managing unexpected bleeding or organ injury are particularly welcome. This session aims to bring together the collective wisdom required to serve as the last line of defense in open HBP surgery, thereby contributing to further improvements in surgical safety.
While laparoscopic cholecystectomy is the standard procedure for acute cholecystitis, difficult cases with severe inflammation remain a challenge for many surgeons. To avoid the critical complication of bile duct injury, precise situational judgment and a broad repertoire of technical options, including bail-out strategies like subtotal cholecystectomy, are required.
This video workshop focuses on "practical judgments and techniques for safety, directly applicable to daily practice." We are seeking videos filled with practical wisdom and techniques on how to safely navigate difficult situations, such as the timing for deciding on a bail-out strategy and the practical applications of ICG fluorescence for bile duct identification. We aim for this to be a forum where the sharing of experiences through video directly contributes to enhancing surgical safety in daily clinical practice.
Pancreaticobiliary maljunction and congenital biliary dilatation are high-risk conditions for biliary tract cancer, for which the standard treatment is resection of the dilated bile duct and biliary reconstruction to prevent carcinogenesis. In recent years, minimally invasive approaches such as laparoscopic and robotic-assisted surgery have been introduced for this established procedure, and the techniques continue to evolve.
In this video workshop, we invite presentations on tips for safe hilar dissection in minimally invasive surgery, techniques for reliable, stricture-free cholangiojejunostomy, and the optimization of surgical procedures tailored to various cases, including open surgery. Through the sharing of techniques via video, this session will serve as a forum for discussion aimed at standardizing procedures and improving safety for patients with these conditions.
In spleen-preserving distal pancreatectomy for benign and low-grade malignant pancreatic tumors, splenic vessel preservation (Kimura technique) and splenic vessel resection (Warshaw technique) each have distinct advantages and challenges. This is an important topic requiring multifaceted examination including splenic function preservation, surgical safety, and long-term complication rates.
This debate will feature constructive discussion between advocates of both techniques. Advocates of splenic vessel preservation will argue the superiority of maintaining splenic function through blood flow preservation, while advocates of splenic vessel resection will present their case for surgical simplicity and safety. We expect valuable discussions on case selection criteria, complication management, and long-term outcome comparisons that will provide practical guidelines for clinical decision-making.
No consensus has been reached on whether to prioritize chemotherapy or hepatectomy when deciding the treatment strategy for resectable multiple colorectal liver metastases. While neoadjuvant chemotherapy offers the advantages of controlling micrometastases and assessing chemo-sensitivity, an upfront surgery has the benefits of definitive tumor removal and avoiding the loss of a resection opportunity.
This debate session will focus on this critical clinical question. By clarifying the pros and cons of each approach from the perspective of their respective advocates, we aim to create a thought-provoking discussion that can aid in clinical decision-making.
This session will be led by a native English-speaking editor specializing in English-language medical manuscripts, providing fundamental training on effective presentation skills.
Following presentations of a case report or case series, participants will receive detailed feedback on their English expressions, pronunciation, presentation style, and overall structure. Ample time for personalized advice will be provided, serving as an intensive training opportunity for young physicians.
Eligibility: Physicians under 40 years of age, including residents.
※As with free paper (poster) presentations, please select both a “Disease” and an “Area” from the list below.
Residents and students interested in hepatobiliary and pancreatic surgery are highly encouraged to apply.
| Diseases | Areas |
|---|---|
| 01. Liver (benign) | 01. Diagnosis |
| 02. Liver (malignant) | 02. Surgery |
| 03. Pancreas (benign) | 03. Endoscopic surgery |
| 04. Pancreas (malignant) | 04. Postoperative complications |
| 05. Biliary tract (benign) | 05. Treatment |
| 06. Biliary tract (malignant) | 06. Other |
| 07. Other |
© 2025 The 38th Meeting of
Japanese Society of Hepato-Biliary-Pancreatic Surgery